The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it

Breast

Volumn 20, Issue SUPPL. 3, 2011, Pages

  Lazzeroni, Matteo ^a,b   Gandini, Sara ^a   Puntoni, Matteo ^c   Bonanni, Bernardo ^a   Gennari, Alessandra ^c   DeCensi, Andrea ^c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c GALLIERA HOSPITAL   (Italy)

Author keywords

Antioxidants; Breast Cancer; Chemoprevention; Fenretinide; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; CALCITRIOL; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; FENRETINIDE; FOLIC ACID; NATURAL PRODUCT; PLACEBO; RETINOL; SELENIUM; VITAMIN; VITAMIN D;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CLINICAL TRIAL (TOPIC); DARK ADAPTATION; DIET THERAPY; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; EVIDENCE BASED MEDICINE; FOLIC ACID BLOOD LEVEL; GENETIC POLYMORPHISM; HIGH RISK POPULATION; HUMAN; NONHUMAN; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; OVARY CANCER; OXIDATIVE STRESS; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; TREATMENT DURATION; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 80054864091     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/S0960-9776(11)70292-2     Document Type: Review

References (69)

1. Halliwell B Free radicals and antioxidants - quo vadis?. Trends Pharmacol Sti 2011, 32:125-130.
2. Machlin LJ, Bendich A Free radical tissue damage: protective role of antioxidant nutrients. FASEBJ 1987, 1:441-445.
3. Diplock AT Antioxidants and disease prevention. Mol AspectsMed 1994, 15:293-376.
4. van PG, van den BH Vitamins and cancer. Cancer Lett 1997, 114:195-202.
5. Diplock AT, Charleux JL, Crozier-Willi G, et al. Functional food science and defence against reactive oxidative species. BrJNutr 1998, 80(Suppl 1):S77-112.
6. Balluz LS, Kieszak SM, Philen RM, Mulinare J Vitamin and mineral supplement use in the United States. Results from the third National Health and Nutrition Examination Survey. Arch Fam Med 2000, 9:258-262.
7. Radimer K, Bindewald B, Hughes J, et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 2004, 160:339-349.
8. Millen AE, Dodd KW, Subar AF Use of vitamin, mineral, nonvitamin, and nonmineral supplements in the United States: The 1987, 1992, and 2000 National Health Interview Survey resultsj/4m. Diet Assoc 2004, 104:942-950.
9. Nichter M, Thompson JJ For my wellness, not just my illness: North Americans' use of dietary supplements. Cult Med Psychiatry 2006, 30:175-222.
10. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C Antioxidant supplements for preventing gastrointestinal cancers. Cochrane Database Syst Rev 2008, CD004183.
11. Bjelakovic G, Nikolova D, Simonetti RG, Gluud C Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004, 364:1219-1228.
12. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007, 297:842-857.
13. Halliwell B Free radicals, antioxidants, and human disease: curiosity, cause, or consequence?. Lancet 1994, 344:721-724.
14. Salganik RI The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human populationJ/4m. Coll Nutr 2001, 20:464S-472S.
15. Simon HU, Haj-Yehia A, Levi-Schaffer F Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000, 5:415-418.
16. Kimura H, Sawada T, Oshima S, et al. Toxicity and roles of reactive oxygen species. Curr Drug Targets Lnflamm Allergy 2005, 4:489-495.
17. Bast A, Haenen GRMM The toxicity of antioxidants and their metabolites. Environmental Toxicology and Pharmacology 2002, 11:251-258.
18. Ratnam DV, Ankola DD, Bhardwaj V, Sahana DK, Kumar MN Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. J Control Release 2006, 113:189-207.
19. Lewis SJ, Harbord RM, Harris R, Smith GD Meta-analyses of observational and genetic association studies of folate intakes or levels and breast cancer risk. J Natl Cancer Lnst 2006, 98:1607-1622.
20. Deeb KK, Trump DL, Johnson CS Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007, 7:684-700.
21. Autier P, Gandini S Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007, 167:1730-1737.
22. Visser M, Deeg DJ, Puts MT, Seidell JC, Lips P Low serum concentrations of 25-hydroxyvitamin D in older persons and the risk of nursing home admission. Am J Clin Nutr 2006, 84:616-622.
23. Melamed ML, Michos ED, Post W, Astor B 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008, 168:1629-1637.
24. Garland CF, Comstock GW, Garland FC, et al. Serum 25-hydroxyvitamin D and colon cancer: eight-year prospective study. Lancet 1989, 2:1176-1178.
25. Tuohimaa R, Tenkanen L, Ahonen M, et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. LntJ Cancer 2004, 108:104-108.
26. Wang AY, Lam CW, Sanderson JE, et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. AmJ Clin Nutr 2008, 87:1631-1638.
27. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006, 354:684-696.
28. Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Lnst 2008, 100:1581-1591.
29. Holick MF Calcium plus vitamin D and the risk of colorectal cancer. N Engl J Med 2006, 354:2287-2288.
30. Giovannucci E Calcium plus vitamin D and the risk of colorectal cancer. N Engl J Med 2006, 354:2287-2288.
31. IARC Working Group. Vitamin D and Cancer. 2008.
32. Gandini S, Boniol M, Haukka J, et al. Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. lntJ Cancer 2011, 128:1414-1424.
33. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 2009, 27:3757-3763.
34. Holick MF, Chen TC Vitamin D deficiency: a worldwide problem with health consequences. AmJ Clin Nutr 2008, 87:1080S-1086S.
35. Holick MF Vitamin D deficiency. N EnglJ Med 2007, 357:266-281.
36. Gorham ED, Garland CF, Garland FC, et al. Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol 2005, 97:179-194.
37. Bischoff-Ferrari HA, Giovannucci E, Willett WC, Dietrich T, wson-Hughes B Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. AmJ Clin Nutr 2006, 84:18-28.
38. Chambon P A decade of molecular biology of retinoic acid receptors. FASEB J 1996, 10:940-954.
39. Cobleigh MA Breast cancer and fenretinide, an analogue of vitamin A. Leukemia 1994, 8(Suppl 3):S59-S63.
40. Sporn MB, Dunlop NM, Newton DL, Smith JM Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976, 35:1332-1338.
41. Mehta RG, Moon RC, Hawthorne M, Formelli F, Costa A Distribution of fenretinide in the mammary gland of breast cancer patients. Eur J Cancer 1991, 27:138-141.
42. Moon RC, Pritchard JF, Mehta RG, et al. Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor. Carcinogenesis 1989, 10:1645-1649.
43. Green A, Shilkaitis A Christov IC 4-(hydroxyphenyl)retinamide selectively inhibits the development and progression of ductal hyperplastic lesions and carcinoma in situ in mammary gland. Carcinogenesis 1999, 20:1535-1540.
44. Sheikh MS, Shao ZM, Li XS, et al. N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 1995, 16:2477-2486.
45. Fanjul AN, Delia D, Pierotti MA, et al. 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 1996, 271:22441-22446.
46. Sun SY, Li W, Yue R, et al. Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms. Cancer Res 1999, 59:2493-2498.
47. Simeone AM, Tari AM How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 2004, 61:1475-1484.
48. Liu G, Wu M, Levi G, Ferrari N Inhibition of cancer cell growth by all-trans retinoic acid and its analog N-(4-hydroxyphenyl) retinamide: a possible mechanism of action via regulation of retinoid receptors expression. IntJ Cancer 1998, 78:248-254.
49. Sabichi AL, Hendricks DT, Bober MA, Birrer MJ Retinoic acid receptor beta expression and growth inhibition of gynecologic cancer cells by the synthetic retinoid N-(4-hydroxyphenyl) retinamideJNat/. Cancer Inst 1998, 90:597-605.
50. Panigone S, Debernardi S, Taya Y, et al. pRb and Cdk regulation by N-(4-hydroxyphenyl)retinamide. Oncogene 2000, 19:4035-4041.
51. Lotan R Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J Nat/. Cancer Inst 1995, 87:1655-1657.
52. Wu JM, DiPietrantonio AM, Hsieh TC Mechanism of fenretinide (4-HPR)-induced cell death. Apoptosis 2001, 6:377-388.
53. Delia D, Aiello A, Meroni L, et al. Role of antioxidants and intracellular free radicals in retinamide-induced cell death. Carcinogenesis 1997, 18:943-948.
54. Oridate N, Suzuki S, Higuchi M, et al. Involvement of reactive oxygen species in N-(4-hydroxyphenyl)retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997, 89:1191-1198.
55. Tosetti F, Vene R, Arena G, et al. N-(4-hydroxyphenyl)retinamide inhibits retinoblastoma growth through reactive oxygen species-mediated cell death. Mol Pharmacol 2003, 63:565-573.
56. Simeone AM, Ekmekcioglu S, Broemeling LD, Grimm EA, Tari AM A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. Mol Cancer Ther 2002, 1:1009-1017.
57. Simeone AM, Broemeling LD, Rosenblum J, Tari AM HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production. Oncogene 2003, 22:6739-6747.
58. Maurer BJ, Melton L, Billups C, Cabot MC, Reynolds CP Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J Natl Cancer Inst 2000, 92:1897-1909.
59. Umansky V, Ushmorov A, Ratter F, et al. Nitric oxide-mediated apoptosis in human breast cancer cells requires changes in mitochondrial functions and is independent of CD95 (APO-1/Fas). IntJ Oncol 2000, 16:109-117.
60. Hail N, Kim HJ, Lotan R Mechanisms of fenretinide-induced apoptosis. Apoptosis 2006, 11:1677-1694.
61. Veronesi U, Mariani L, Decensi A, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006, 17:1065-1071.
62. Favoni RE, de Cupis A, Bruno S, et al. Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. BrJ Cancer 1998, 77:2138-2147.
63. Fontana JA, Burrows-Mezu A, Clemmons DR, LeRoith D Retinoid modulation of insulin-like growth factor-binding proteins and inhibition of breast carcinoma proliferation. Endocrinology 1991, 128:1115-1122.
64. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998, 351:1393-1396.
65. Torrisi R, Parodi S, Fontana V, et al. Effect of fenretinide on plasma IGF-I and IGFBP-3 in early breast cancer patients. IntJ Cancer 1998, 76:787-790.
66. Decensi A, Veronesi U, Miceli R, et al. Relationships between plasma insulinlike growth factor-I and insulin-like growth factor binding protein-3 and second breast cancer risk in a prevention trial of fenretinide. Clin Cancer Res 2003, 9:4722-4729.
67. Simeone AM, Deng CX, Kelloff GJ, et al. N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCAl-mutated breast cancer cells. Carcinogenesis 2005, 26:1000-1007.
68. Brewer M, Kirkpatrick ND, Wharton JT, et al. 4-HPR modulates gene expression in ovarian cells. IntJ Cancer 2006, 119:1005-1013.
69. Bonanni B, Lazzeroni M, Veronesi U Synthetic retinoid fenretinide in breast cancer chemoprevention. Expert Rev Anticancer Ther 2007, 7:423-432.